The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,669.50
Bid: 1,669.00
Ask: 1,669.50
Change: -0.50 (-0.03%)
Spread: 0.50 (0.03%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-MARKET PULSE-Neurocrine Biosciences, AMD, L&L Energy, BlackBerry, Microsoft

Tue, 10th Sep 2013 11:30

(Corrects link to market report)

Sept. 10 (Reuters) - Some U.S. stocks to watch on Tuesday:

FUTURES CLIMB ON ROSY CHINA DATA, EASING SYRIA FEARS

U.S. stock index futures rose on Tuesday, putting the S&P500 on track for a sixth day of gains, following another batchof rosy economic data out of China and as expectations easedabout a Western military strike against Syria.

S&P 500 futures rose 8.9 points and were above fairvalue, a formula that evaluates pricing by taking into accountinterest rates, dividends and time to expiration on thecontract. Dow Jones industrial average futures gained 76points, and Nasdaq 100 futures added 19 points.

** ADVANCED MICRO DEVICES INC, Monday close $3.69,up 2 pct premarket

The chipmaker, targeting new markets as personal computersales decline, unveiled chips designed to run slot machines,factory robots, airport signs, medical equipment and otherdevices.

** NEUROCRINE BIOSCIENCES INC, Monday close $16.70,down 28 pct premarket

The company said on Monday that a lower dose of itsexperimental drug to treat a rare movement disorder did not meetthe main goal of a mid-stage clinical study.

Cowen and Co cut its price target on the stock to $19 from$20 while MKM Partners cut its target to $13.50 from $17.00 andOppenheimer to $15 from $19.

** L&L ENERGY INC, Monday close $2.89, up 15 pctafter market

The coal miner's first-quarter profit more than doubled asproduction was boosted by the acquisition of two mines in Chinain November. Production rose 54 percent to 228,000 tons in thequarter.

** FIVE BELOW INC, Monday close $41.04, up 14 pctafter market

The specialty value retailer reported better-than-expectedresults for the second quarter due to a 6.6 percent increase insame-store sales. The company also raised its full-year earningsand revenue forecast.

** PVH CORP, Monday close $132.11, down 4.4 pctafter market

The maker of Calvin Klein and Tommy Hilfiger clothes gave athird-quarter sales and profit forecast that was below analysts'estimates. The company characterized the global environment as"challenging".

** BLACKBERRY LTD, Monday close $11.53, down 4 pctpremarket

The Canadian company's biggest shareholder has approachedseveral large Canadian investment funds about forging a deal totake the smartphone maker private, but the proposal is still "anairy-fairy, 'what if' kind of thing," according to a source withdirect knowledge of the situation.

** GLAXOSMITHKLINE PLC, Monday close $50.46, down 1pct premarket

The threat of generic copies of the company's best-sellinglung drug Advair finally making it to the market in the UnitedStates hit confidence in the drugmaker.

** MICROSOFT CORP, Monday close $31.65, up 1 pctpremarket

At least three of the top 20 investors in the company want aturnaround expert to succeed Steve Ballmer as chief executive.They have urged the technology giant's board to consider FordMotor Co Chief Executive Alan Mulally and ComputerSciences Corp Chief Executive Mike Lawrie for the job,several sources familiar with the matter said.

** MCDONALD'S CORP, Monday close $96.45

The fast food chain reported a better-than-expected 1.9percent rise in global sales at established restaurants inAugust, boosted by stronger sales in Europe. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.